Owkin has launched a comprehensive multimodal patient data discovery program to accelerate multimodal data access and advance medical research.
Initiated in September 2024, the program will map 11 therapeutic areas across Owkin's extensive transatlantic network, with completion expected by May 2025. The data discovered in this program will power Owkin K, Owkin’s software, driving faster discoveries.
This program encompasses multiple oncology indications, including non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), breast cancer, prostate cancer, ovarian cancer, pancreatic cancer, and multiple myeloma (MM). The program also covers three immunology and inflammation (I&I) areas—ulcerative colitis (UC), Crohn's disease (CD), and systemic lupus erythematosus (SLE)—as well as Alzheimer's disease (AD) in neurology.
